Kenneth M. Verburg

Pfizer (United States) — United States

Medicine · Health Sciences

39h-index10.6kcitations107works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Inflammatory mediators and NSAID effects(59), Osteoarthritis Treatment and Mechanisms(22), Anesthesia and Pain Management(17), Rheumatoid Arthritis Research and Therapies(14), Pain Mechanisms and Treatments(13)

Publications107 total

Characterization of adverse joint outcomes in patients with osteoarthritis treated with subcutaneous tanezumab
Osteoarthritis and Cartilage·2023· 22 citedOpen Access
Predicting Treatment Responses in Patients With Osteoarthritis: Results From Two Phase III Tanezumab Randomized Clinical Trials
Clinical Pharmacology & Therapeutics·2023· 13 citedOpen Access
Clinical Meaningfulness of Response to Tanezumab in Patients with Chronic Low Back Pain: Analysis From a 56-Week, Randomized, Placebo- and Tramadol-Controlled, Phase 3 Trial
Pain and Therapy·2022· 5 citedOpen Access
Observed efficacy and clinically important improvements in participants with osteoarthritis treated with subcutaneous tanezumab: results from a 56-week randomized NSAID-controlled study
Arthritis Research & Therapy·2022· 24 citedOpen Access
Neurological safety of subcutaneous tanezumab versus NSAID in patients with osteoarthritis
Journal of the Neurological Sciences·2022· 7 cited
Tanezumab for Chronic low Back Pain: A Long-Term, Randomized, Celecoxib-Controlled Japanese Phase III Safety Study
Pain Management·2021· 9 citedOpen Access
Single and Composite Endpoints of Within-Patient Improvement in Symptoms: Pooled Tanezumab Data in Patients with Osteoarthritis
Rheumatology and Therapy·2021· 3 citedOpen Access
Postoperative Outcome of Patients Who Underwent Total Joint Replacement During the Tanezumab Phase 3 Osteoarthritis Development Program: A 24-Week Observational Study
Surgical Technology Online·2021· 2 cited
Peripheral Neurological Safety of Subcutaneous Tanezumab versus Placebo or NSAIDs in Patients with Osteoarthritis. (1937)
Neurology·2021
Research approaches for evaluating opioid sparing in clinical trials of acute and chronic pain treatments: Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials recommendations
Pain·2021· 44 citedOpen Access
Total joint replacements in three phase 3 studies of tanezumab in patients with osteoarthritis
Osteoarthritis and Cartilage·2021Open Access
Subcutaneous tanezumab for osteoarthritis: Is the early improvement in pain and function meaningful and sustained?
European Journal of Pain·2021· 10 citedOpen Access
Long‐Term Safety and Efficacy of Subcutaneous Tanezumab Versus Nonsteroidal Antiinflammatory Drugs for Hip or Knee Osteoarthritis: A Randomized Trial
Arthritis & Rheumatology·2021· 72 cited
Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period
Annals of the Rheumatic Diseases·2020· 153 citedOpen Access
OP0090 EFFICACY OF SUBCUTANEOUS TANEZUMAB FOR THE TREATMENT OF CHRONIC LOW BACK PAIN: AN ANALYSIS OF BRIEF PAIN INVENTORY-SHORT FORM SCORES FROM A 56-WEEK, RANDOMIZED, PLACEBO- AND TRAMADOL-CONTROLLED, PHASE 3 TRIAL
Annals of the Rheumatic Diseases·2020Open Access
Tanezumab for chronic low back pain: a randomized, double-blind, placebo- and active-controlled, phase 3 study of efficacy and safety
Pain·2020· 54 citedOpen Access
Response to: ‘Use of tanezumab for patients with hip and knee osteoarthritis with reference to a randomised clinical trial by Berenbaum and colleagues’ by Riddle and Perera
Annals of the Rheumatic Diseases·2020Open Access
Subcutaneous Tanezumab Versus Placebo or Tramadol in Patients with Chronic Low Back Pain: 16- Week Efficacy and Safety Results from a Phase 3 Study (305)
Neurology·2020
Subcutaneous Tanezumab Versus Tramadol for Chronic Low Back Pain: Efficacy and Safety Results from a 56-Week Phase 3 Study with a 24-Week Follow Up Period (306)
Neurology·2020
Postoperative outcome of patients who underwent total joint replacement during the tanezumab phase 3 osteoarthritis development program: a 24-week observational study
Osteoarthritis and Cartilage·2020· 1 cited
page 1 of 6Next →

Frequent Co-authors

Christine R. West(16), Mark T. Brown(9), Andrew Whelton(7), Gilbert Geis(7), David P. Recker(7), Richard C. Vari(6), Jeffrey D. Kent(5), Alan Kivitz(5), Michael D. Smith(5), R. H. Freeman(5), Daniel Villarreal(5), James O. Davis(5), Jay L. Goldstein(4), J B Lefkowith(4), Richard C. Hubbard(4), Peter C. Isakson(4), William W. Zhao(4), Lars Viktrup(4), M. Brown(4), Joseph Gimbel(4)